Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Terbinafine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.97 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 3/20 | 0.97 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.97 |
| ▸ | KCNH2 known ✓ | Q12809 | 3/20 | 0.61 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.61 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.61 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.61 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.61 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.61 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.61 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.61 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.97 |
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | SQLE | Q14534 | 2/20 | 0.97 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terbinafine SCHEMBL36795 | 1.00 | CYP2D6 (0.97) | CYP2D6LMNASLC6A2SIGMAR1ADRA2A | |
| Terbinafine SCHEMBL29871278 | 1.00 | CYP2D6 (0.97) | CYP2D6LMNASLC6A2SIGMAR1ADRA2A | |
| Terbinafine SCHEMBL29365335 | 1.00 | CYP2D6 (0.97) | CYP2D6LMNASLC6A2SIGMAR1ADRA2A | |
| Terbinafine SCHEMBL29216417 | 1.00 | CYP2D6 (0.97) | CYP2D6LMNASLC6A2SIGMAR1ADRA2A | |
| Terbinafine SCHEMBL29066152 | 0.99 | CYP2D6 (0.95) | CYP2D6LMNASLC6A2SIGMAR1ADRA2A | |
| Terbinafine SCHEMBL5279646 | 0.99 | CYP2D6 (1.00) | CYP2D6LMNASLC6A2SIGMAR1ADRA2A | |
| Terbinafine SCHEMBL37843 | 0.99 | CYP2D6 (1.00) | CYP2D6LMNASLC6A2SIGMAR1ADRA2A | |
| Terbinafine SCHEMBL31374681 | 0.99 | CYP2D6 (1.00) | CYP2D6LMNASLC6A2SIGMAR1ADRA2A | |
| Terbinafine SCHEMBL2028187 | 0.99 | CYP2D6 (1.00) | CYP2D6LMNASLC6A2SIGMAR1ADRA2A | |
| Terbinafine SCHEMBL2042785 | 0.99 | CYP2D6 (1.00) | CYP2D6LMNASLC6A2SIGMAR1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5120 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122057027-A | Spray containing terbinafine hydrochloride and preparation method thereof | 江苏知原药业股份有限公司 | 2026-05-19 | — | — | CN | claimed |
| US-12594260-B2 | Topical formulations for infections | Topical Rx, LLC (US) | 2026-04-07 | — | — | US | claimed |
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | ATOPIC MEDICAL INC (US) | 2026-01-29 | — | — | US | claimed |
| US-20260000649-A1 | TOPICAL FORMULATIONS FOR INFECTIONS | TOPICAL RX LLC (US) | 2026-01-01 | — | — | US | claimed |
| US-20260000678-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION | TAKASAKI UNIV OF HEALTH AND WELFARE (JP) | 2026-01-01 | — | — | US | claimed |
| US-20250332120-A1 | COMPOSITION FOR EXTERNAL PREPARATION | KAO CORPORATION (JP) | 2025-10-30 | — | — | US | claimed |
| US-12433856-B2 | Petrolatum-based compositions and methods of treatment for onychomycosis | GLOBAL HEALTH SOLUTIONS LLC | 2025-10-07 | — | — | US | claimed |
| CN-119564596-A | Terbinafine hydrochloride needleless injection, percutaneous injection for treating shallow fungal infection and administration device thereof | 江苏乐聚医药科技有限公司 | 2025-03-07 | — | — | CN | claimed |
| CN-115073303-B | Preparation method of terbinafine hydrochloride Z-type isomer | 乐泰药业(兰西)有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-119385986-A | Venturi effect preparation method of terbinafine film-forming composition | 江苏知原药业股份有限公司 | 2025-02-07 | — | — | CN | claimed |
| EP-1024814-A2 | USE OF ANTIFUNGAL AGENTS FOR THE TOPICAL TREATMENT OF FUNGUS-INDUCED MUCOSITIS | Ponikau, Jens (US) | 2000-08-09 | — | — | EP | claimed |
| EP-0503988-B1 | Compositions to treat onychomycoses | NOVARTIS AG (CH) | 2000-03-15 | — | — | EP | claimed |
| US-6017920-A | Antifungal composition for external use being retentive in stratum corneum | TOKO YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 2000-01-25 | — | — | US | claimed |
| EP-0925308-A2 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN | Micrologix Biotech, Inc. (CA) | 1999-06-30 | — | — | EP | claimed |
| WO-1999020261-A2 | USE OF ANTIGUNAL AGENTS FOR THE TOPIAL TREATMENT OF FUNGUS-INDUCED MUCOSITIS | PONIKAU JENS (US) | 1999-04-29 | — | — | WO | claimed |
| US-5814305-A | TREATING NAIL FUNGI INFECTIONS | NOVARTIS AG (CH) | 1998-09-29 | — | — | US | claimed |
| WO-1998007745-A9 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN | — | 1998-04-23 | — | — | WO | claimed |
| WO-1998007745-A2 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN | MICROLOGIX BIOTECH, INC. (CA) | 1998-02-26 | — | — | WO | claimed |
| US-5661170-A | APPLYING TO SKIN AN AQUEOUS CLEANSER CONTAINING BENZALKONIUM CHLORIDE, ALLANTOIN, SURFACTANT | WOODWARD LABORATORIES, INC. (US) | 1997-08-26 | — | — | US | claimed |
| EP-0715856-A1 | KERATIN-STORABLE ANTIFUNGAL COMPOSITION FOR EXTERNAL USE | TOKO YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 1996-06-12 | — | — | EP | claimed |